Cell line · CVCL_0037
Papers97
1 to 20 of 97
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells. | ACS Omega | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A guide to selecting high-performing antibodies for Netrin-1 (UniProt ID: O95631) for use in western blot and immunoprecipitation. | F1000Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Oral Fungal Infection Impacts Epithelial Innate Immunity to Promote Local and Distal Squamous Cell Carcinoma Progression. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Volume EM reveals desmosome three-dimensional architecture in epithelial cells and tissue models. | J Cell Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lipid packing contributes to the confinement of caveolae to the plasma membrane. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma. | Mol Ther Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| THC and CBD Induce Heme Oxygenase-1-Dependent Cell Death and Trigger Mitochondrial Dysfunction in Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells. | Antioxidants (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An estrogen receptor/E2F1/CDKN3 axis protects from UV-induced skin cancers in females. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Solute carrier family (SLC) amino acid transporters are upregulated in cutaneous squamous cell carcinoma. | Biol Direct | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identification of PI3K/AKT/mTOR-related genes as diagnostic biomarkers for cutaneous squamous cell carcinoma. | Biochem Biophys Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PLK4 is a potential therapeutic target in nonmelanoma skin cancers: Evidence from molecular and in vivo studies. | Photochem Photobiol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing the in vitro anticancer efficacy of Paclitaxel against triple-negative breast cancer via an exopolysaccharide from a haloalkaliphilic archaeal strain. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tks5 interactome reveals endoplasmic-reticulum-associated translation machinery in invadosomes. | FEBS J | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0037/papers